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The study was aimed at analysing the frequency of impulse control disorders (ICDs) and compulsive 
behaviours (CBs) in patients with Parkinson’s disease (PD) and in control subjects (CS) as well as the 
relationship between ICDs/CBs and motor, nonmotor features and dopaminergic treatment in PD 
patients. Data came from COPPADIS‑2015, an observational, descriptive, nationwide (Spain) study. 
We used the validated Questionnaire for impulsive‑compulsive Disorders in parkinson’s Disease‑
Rating Scale (QUIP‑RS) for ICD/CB screening. The association between demographic data and ICDs/
CBs was analyzed in both groups. In PD, this relationship was evaluated using clinical features and 
treatment‑related data. As result, 613 PD patients (mean age 62.47 ± 9.09 years, 59.87% men) and 
179 CS (mean age 60.84 ± 8.33 years, 47.48% men) were included. ICDs and CBs were more frequent 
in PD (ICDs 12.7% vs. 1.6%, p < 0.001; CBs 7.18% vs. 1.67%, p = 0.01). PD patients had more frequent 
previous ICDs history, premorbid impulsive personality and antidepressant treatment (p < 0.05) 
compared with CS. In PD, patients with ICDs/CBs presented younger age at disease onset, more 
frequent history of previous ICDs and premorbid personality (p < 0.05), as well as higher comorbidity 
with nonmotor symptoms, including depression and poor quality of life. Treatment with dopamine 
agonists increased the risk of ICDs/CBs, being dose dependent (p < 0.05). As conclusions, ICDs and 
CBs were more frequent in patients with PD than in CS. More nonmotor symptoms were present 
in patients with PD who had ICDs/CBs compared with those without. Dopamine agonists have a 
prominent effect on ICDs/CBs, which could be influenced by dose.
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Impulse control disorders (ICDs) and compulsive behaviours (CBs) are known conditions that frequently appear 
in patients with Parkinson’s disease (PD). Within the ICDs spectrum, pathological gambling, compulsive shop-
ping, hypersexuality and compulsive eating are included. CBs are those related to the performing of aimless 
repetitive stereotyped complex tasks, known as punding, hobbysm, excessive and aimless wandering (“walka-
bout”) and dysregulation dopaminergic syndrome (DDS)1.
The etiopathology of these disorders is not simple. Demographic factors, premorbidities, comorbidities and 
genetic factors can influence the risk of ICDs and  CBs2–5. Comorbidities such as tobacco consumption and 
depression are well-established factors linked to ICDs. However, the directionality of the association between 
ICDs and affective disorders is not still  clear6–8. Epidemiologic factors such as sex, age and age at onset could 
influence the incidence of ICDs and  CBs1. Nevertheless, it is controversial whether these disorders are exclusively 
linked to the first years of disease evolution when patients still have an integrum ventral  striatum2, or whether 
they are associated with longer exposure to dopamine  treatment3. On the other hand, estimated prevalence rates 
across countries range from 10 to 39%4. This wide range depends on the study characteristics, but also on the 
population features, being therefore important the assessment of specific populations.
In addition, it is known that dopaminergic replacement therapy (DRT) plays an important role in ICDs 
and CBs, given their prevalence in untreated de novo patients is the same as in control subjects (CS)8. Thus, 
under external dopaminergic stimulation by DRT, the regulation of mesocorticolimbic pathway activity might 
be inappropriate, inducing an aberrant response to reward tasks and impulsivity  traits9. Despite this fact, not 
all patients undergoing DRT treatment have ICDs or CBs, suggesting the action of a neurobiological substrate 
leading to individual  susceptibility5.
Dopamine agonists (DA) have been shown to be a principal drug involved in ICDs, and the association 
appears to be dose  dependent10,11. However, there is controversy regarding DA dose and ICDs, given it is not 
fully understood whether the ICDs are associated with the DA dose alone or in combination with the dose of 
levodopa and other dopaminergic  drugs2,3,12.
Parkinsonian features have also been associated with ICDs. Not only can cognitive performance in patients 
with ICDs be impaired, but executive dysfunction as well as impairment in the reward-related decision process 
and set shifting can be  present6,13,14.
Taking into account the factors influencing ICDs and CBs in PD, we sought to assess clinical features linked 
to these disorders in the COPPADIS-2015 population of PD and CS. We especially aimed to evaluate the impact 
of DRT and the influence of clinical features on these disorders in the PD population.
Methods
participants. The participant data was drawn from the baseline assessment of the COPPADIS-2015, an 
observational, descriptive, 5-year follow-up, nationwide (Spain) evaluation  study15. The project is conducted in 
accordance with the standards for Good Clinical Practice and the fundamental ethical principles established in 
the Declaration of Helsinki. Approval of the Ethics Committee at each center was obtained (see Supplementary 
Material Table 6) and informed consent was obtained for each participant. COPPADIS-2015 was classified by the 
AEMPS (Agencia Española del Medicamento y Productos Sanitarios) as a Post-authorization Prospective Follow-
up study with the code COH-PAK-2014-01.
A total of 694 patients with PD (mean age 62.6 ± 8.9 years, 60.3% men) and 207 CS (mean age 61 ± 8.3 years, 
49.5% men) were included in the COPPADIS  study15.
Assessments. The Questionnaire for Impulsive-Compulsive Disorders in Parkinson’s Disease Rating Scale 
(QUIP-RS) was assessed in both patients with PD and CS for screening of ICDs and CBs (cutoff points: gam-
bling ≥ 6, shopping ≥ 8, sex ≥ 8, eating ≥ 7, hobbysm-punding ≥ 7)16. For DDS, we used the investigator criterion, 
given there is no established cut-off.
Demographic data concerning educational level, marital status, smoking, alcohol intake, premorbid impulsive 
personality, previous ICDs and family history of ICDs were collected for both groups (patients with PD and CS).
Data analysis. In the PD group, a cross-sectional assessment was performed for each patient according to 
the study  methodology15. Baseline data were used for the analysis.
Subanalyses of the group with an age at disease onset younger than 50 years and of the DA treatment group 
were also performed.
Parametric univariate tests (t-test and chi-squared test) and nonparametric univariate tests (Wilcoxon test) 
were used to compare demographics and QUIP-RS results between the CS and the patients with PD. A logistic 
regression analysis (controlling for sex and age) was also used.
In the PD group analysis, univariate and multivariate analysis were used to compare demographic variables, 
motor and nonmotor symptoms and dopaminergic treatment variables between patients with PD with and 
without ICDs/CBs. While controlling for age, age at disease onset and disease progression time, a multivariate 
linear regression analysis was used for the quantitative variables and a logistic regression analysis was employed 
for the categorical variables. Finally, the association between ICDs severity and treatment was analysed using 
the QUIP-RS score as the outcome variable and dopaminergic treatment variables (type of treatment and lev-
odopa-equivalent daily dose) as independent variables in multivariate linear regressions (controlling for age, 
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Results
Participants and prevalence of ICDs and CBs. Within the COPPADIS sample, 613 patients with PD 
and 179 CS completed the ICDs and CBs evaluation. ICDs and CBs were more frequent in patients with PD 
compared with the CS (ICDs 12.7% vs. 1.6%, respectively, p < 0.001; CBs 7.18% vs. 1.67%, respectively, p = 0.01). 
The most frequent ICD was compulsive eating in both groups and hobbysm-punding in terms of CBs (Fig. 1).
The analysis split by sex showed a higher presence of hypersexuality in male patients with PD (4.5% vs. 
0.16%, p < 0.001). In the CS, the presence of hypersexuality was higher in the male participants, but it was not 
significant (0.55% vs. 0%, p = 0.85).
Demographic characteristics of the participants with PD and CS. The demographic characteristics 
of the sample are shown in Table 1. Patients with PD were older than the CS (62.47 ± 9.09 vs. 60.84 ± 8.33 years, 
respectively; p = 0.004) and were more often men (59.87% vs. 47.48%, respectively; p = 0.004). Premorbid impul-
sive personality (8.65% vs. 1.1%, respectively; p < 0.001) and previous ICDs (16.1% vs. 0%, respectively; p < 0.001) 
were more frequent among patients with PD than CS, in addition to them having a higher rate of antidepressant 
treatment (25.12% vs. 11.73%, respectively; p < 0.001).
Parkinson’s disease features according to ICDs. In the PD group, those with ICDs had a more fre-
quent previous history of ICDs or CBs (17.95% vs. 7.23%; p = 0.01) and premorbid impulsive personality (17.95% 
vs. 6.6%; p = 0.002) (Table 2).
PD patients with ICDs were younger at evaluation (59.46 ± 9.7 vs. 62.9 ± 8.92; p = 0.002) and at disease onset 
(54.28 ± 9.88 vs. 58.42 ± 9.43; p < 0.001) (Table 3).
Concerning the PD features according to the presence of ICDs, the motor characteristics were similar in 
both groups, except for a higher score in the freezing of gait (FOG) scale in patients with ICDs (5.73 ± 5.73 vs. 
3.38 ± 4.23; p < 0.001) (Table 3). However, the differences in nonmotor features as well as in the performance and 
quality of daily living activities were notable. The score on the Non-Motor Symptoms Scale (NMSS) was higher 
in patients with ICDs (60.37 ± 42.48 vs. 41.33 ± 33.77; p < 0.001). In addition, when the NMSS subdomains were 
analysed, the cardiovascular, sleep/fatigue, mood/cognition, attention/memory, urinary, sexual and miscellaneous 
domains had a higher impact on the patients with ICDs (Fig. 2). Along these lines, the Neuropsychiatry Inven-
tory (NPI) showed that, overall, patients with ICDs presented with a more prominent burden of these symptoms 
(8.6 ± 10.28 vs. 5.48 ± 7.32; p = 0.005). In terms of mood, patients with ICDs showed higher rates of depression 
(48.97% vs 65.38%, p = 0.004). Analyzing the subtype of depression according to the Beck Depression Inventory, 
patients with ICDs showed a higher ratio of subclinic and minor depression compared to those without ICDs. 
Anxiety, euphoria and irritability were the features specifically associated with patients with ICDs.
Apart from the NMSS sleep score, the Parkinson’s Disease Sleep Scale showed that patients with ICDs pre-
sented with poorer sleep quality, as shown by a lower score (102.58 ± 25.84 vs 116.83 ± 25.63; p < 0.001).
The cognitive status did not differ between groups. After assessing the separate domains of the Parkinson’s Dis-
ease Cognitive Rating Scale (PD-CRS), we did not find differences between the patients with and without ICDs.
Figure 1.  Distribution of impulse control disorders and compulsive behaviours in both groups. CS control 
subjects, PD Parkinson’s disease patients.
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The quality of life as measured by the 39-item Parkinson’s disease Questionnaire (PDQ-39) was poorer in 
patients with ICDs (23.38 ± 14.93 vs. 15.64 ± 12.36; p < 0.001). Analysing the domains of the PDQ-39, ICDs had 
a higher impact on patients in terms of mobility, activities of daily living, body discomfort, communication, 
cognition and emotional well-being (Fig. 3). ICDs were also associated with a poorer score on the performance of 
daily activities, as shown by a higher motor items score in the Unified Parkinson’s Disease Rating Scale (UPDRS) 
part II in off condition (2.66 ± 1.79 vs. 3.34 ± 2.27; p = 0.009) (Table 3).
Table 1.  Demographic characteristics of Parkinson’s disease and control subjects. Results for univariate 
tests: chi-square test, t test or Wilcoxon test. Significant p values are in bold. ICDs impulse control disorders, 
CBs compulsive behaviours, N number of subjects, M male, F female, SD standard deviation. a Culture level 
(Elementary/Hihg School/University education). b Lifestyle (Married/Married with children/Others/Alone). 
c Habitat (Rural/Semiurban/Urban).
Control subjects Parkinson’s disease p value
N 179 613 –
Demographic
Sex (M/F) 85/94 367/246 0.004
Age (mean ± SD) 60.84 ± 8.33 62.47 ± 9.09 0.004
Culture  levela 55/63/61 259/187/166 0.02
Lifestyleb 132/11/8/28 487/31/28/66 0.29
Habitatc 19/40/120 73/112/426 0.46
Premorbidity
Historical ICDs or CBs 0 (0%) 99 (16.1%) < 0.001
Premorbid impulsive personality 2 (1.1%) 53 (8.65%) < 0.001
Family history of ICDs or CBs 4 (2.2%) 54 (8.8%) 0.92
Family history of PD 30 (16.75%) 170 (27.7%) 0.004
Comorbidity
Antidepressant treatment 21(11.73%) 154(25.12%) < 0.001
Anxiolytic treatment 22 (12.29%) 100 (16.31%) 0.23
Antipsychotic treatment 0 (0%) 13 (2.12%) 0.1
Smoke 79 (44.13%) 233 (38%) 0.16
Alcohol intake 36 (20.11%) 127(20.72%) 0.95
Table 2.  Demographic characteristics of Parkinson’s disease group according to the presence of impulse 
control disorders. Results for univariate tests: chi-square test, t test or Wilcoxon test. Significant p values are 
in bold. ICDs impulse control disorders, CBs compulsive behaviours, N number of subjects, M male, F female, 
SD standard deviation. *Results for multivariate analysis: multivariate linear regression or multivariate logistic 
regression adjusted by age, years of disease duration. *Adjusted by age, years of disease evolution. a Culture level 
(Elementary/Hihg School/University education). b Lifestyle (Married/Married with children/Others/Alone). 
c Habitat (Rural/Semiurban/Urban).
ICDs negative ICDs positive p value
Demographic
Sex (M/F) 318/217 49/29 0.65
Age (mean ± SD) 62.9 ± 8.92 59.46 ± 9.7 0.002
Culture  levela 226/160/148 33/27/18 0.6
Lifestyleb 425/28/23/58 62/3/5/8 0.81
Habitatc 66/95/372 7/17/54 0.53
Premorbidity
Historical ICDs or CBs 39 (7.23%) 14 (17.95%) 0.01
Premorbid impulsive personality 41 (6.6%) 14 (17.95%) 0.002
Familiar history of ICDs or CBs 48 (%) 6 (%) 0.87
Comorbidity
Antidepressant treatment 129 (24.1%) 25 (32%) 0.12*
Anxiolytic treatment 90 (16.8%) 10 (12.82%) 0.43*
Antipsychotic treatment 10 (1.87%) 3 (3.8%) 0.62
Smoking 200 (37.4%) 33 (42.3%) 0.48
Alcohol intake 113 (21.12%) 14 (17.9%) 0.51
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In terms of CBs, the results were similar to those observed for the ICDs (Supplementary Material Table 1). 
There were few exceptions for the age, age at onset, disease progression time and the score of the UPDRS part II 
in off that were similar in the group of CBs positive and negative.
Regarding dopaminergic treatment, we analysed patients receiving DA treatment, levodopa and/or mono-
amine oxidase-B inhibitors. After controlling for levodopa-equivalent dose, we found that ICDs were more 
frequent in patients on DA treatment and the agonist dose was related to the presence of ICDs (237.65 ± 194.72 
vs. 174.72 ± 164.92; p = 0.02) (Table 4).
To analyse the influence of the type of DA, we compared not taking any agonists with the risk linked to each 
type of agonist. For this analysis, we observed that Rotigotine had the lowest risk (OR 2.45; 95% CI 1.06–5.8; 
p = 0.03) and Ropirinole the highest (OR 2.82; 95% CI 1.25–6.57; p = 0.013) (Table 5). Nevertheless, the analysis 
of ICDs risk among agonists did not show statistically significant differences.
To examine the influence of ICDs severity according to treatment, we analysed the QUIP-RS total score 
with dopaminergic treatment characteristics. As expected, we observed that patients with PD undergoing DA 
treatment had a significantly greater QUIP-RS total score compared with the patients with PD without agonist 
treatment, controlling for age, age at disease onset and disease progression time (5.47 ± 9.24 vs. 2.26 ± 5.78, 
respectively; F = 19.39; p < 0.001). When we compared the type of DA with the non-use of DA and the severity 
of ICDs/CBs using the QUIP-RS total score, Ropinirole was associated with the greatest significant increase in 
Table 3.  Motor and non motor evaluations in Parkinson’s disease according to the presence of impulse 
control disorders. Results for univariate test:chi-square test, t test or Wilconxon test. Significant p values are 
in bold. ICDs impulse control disorders, FOG Freezing of Gait Scale, UPDRS Unified Parkinson’s Disease 
Rating Scale, N number of subjects, NMSS Non Motor Symptoms Scale, NPI Neuropsychiatry Inventory, PD 
Parkinson’s disease, PD-CRS Parkinson’s Disease Cognitive Rating Scale, PDQ-39 39 items Parkinson’s Disease 
Questionnaire, PDSS Parkinson’s Disease Sleep Scale, REM rapid eye movements, SD standart deviation, 
WHOQOL-8 8 items World Health Organization Quality of Life. *Results for multivariate analysis: multivariate 
linear regression or multivariate logistic regression adjusted by age, age at onset and years of disease evolution.
ICDs negative ICDs positive p value
Number of subjects 535 78 –
Family history PD N 145 (27.1) 25 (32.05) 0.43
Age at onset Age (mean ± SD) 58.42 ± 9.43 54.28 ± 9.88 < 0.001
Disease progression time Years (mean ± SD) 5.42 ± 4.51 6.25 ± 3.87 0.008
UPDRS score (mean ± SD)
II OFF 2.66 ± 1.79 3.34 ± 2.27 0.009*
II ON 1.69 ± 1.80 1.79 ± 1.99 0.72*
III OFF 22.4 ± 10.97 24.52 ± 12.75 0.22*
III ON 16.18 ± 8.27 15.86 ± 7.74 0.98*
IV 1.91 ± 2.37 2.48 ± 2.42 0.19*
Phenotype (undetermined/PIGD/Tremor) N 80/205/248 17/33/28 0.13
Dominant hemibody N 30/1/149/89/166/100 2/0/24/14/24/14 0.82
Motor fluctuations N (%) 169 (31.56) 29 (37.18) 0.75*
Dyskinesias N (%) 92 (17.19) 14 (17.95) 0.68*
NMSS Score (mean ± SD) 41.33 ± 33.77 60.37 ± 42.48 < 0.001*
PDSS Score (mean ± SD) 116.83 ± 25.63 102.58 ± 25.84  < 0.001*
REM sleep behaviour disorder N (%) 198 (37) 35 (44.87) 0.19
BECK (depression yes) N (%) 262 (48.97) 51 (65.38) 0.004*
BECK score (mean ± SD) 8.24 ± 7.02 12.46 ± 8.51 < 0.001*
BECK-depression inventory
Score (mean ± SD) 8.25 ± 7.02 12.47 ± 8.51  < 0.001*
Subclinic/minor/major 79/89/94 19/16/16 0.38
No depression vs subclinic 273/79 27/19 0.007*
No depression vs minor 273/89 27/16 0.02*
No depression versus major 273/94 27/16 0.11*
FOG Score (mean ± SD) 3.38 ± 4.23 5.73 ± 5.73 < 0.001*
MMSE Score (mean ± SD) 29.21 ± 1 29.15 ± 1.1 0.22*
PD-CRS
Score (mean ± SD) 91.64 ± 15.67 92.56 ± 17.44 0.36*
Non CI/MCI/dementia 374/151/3 55/22/1 0.76*
Fronto-subcortical 63.74 ± 14.39 64.93 ± 15.88 0.49*
Posterior cortical 27.89 ± 2.99 27.63 ± 2.89 0.16*
NPI (severity × frequency) Score (mean ± SD) 5.48 ± 7.32 8.6 ± 10.28 0.005*
PDQ-39 Score (mean ± SD) 15.64 ± 12.36 23.38 ± 14.93 < 0.001*
WHOQOL-8 Score (mean ± SD) 7.33 ± 1.58 6.97 ± 1.61 0.11
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severity (Beta = 4.40; 95% CI 2.44–6.35; F = 7.411; p < 0.001). This result remained significant after correcting 
for confounding variables such as age, age at disease onset and disease progression time (Beta = 3.83; 95% CI 
1.62–6.04; F = 4.773; p < 0.001). Moreover, the increased QUIP-RS total score in patients with ICDs undergoing 
Ropinirole treatment was significant (Beta = 5.97; 95% CI 1.51–10.43; F = 105.6; p < 0.001), but not for patients 
with other types of DA (Fig. 4a). The results were the same when correcting for confounding variables (age, 
age at disease onset and disease progression time )(Beta = 5.99; 95% CI 1.38–10.59; F = 62.35; p < 0.001). On the 
other hand, we observed that the QUIP-RS total score was significantly increased according to DA equivalent 
dose (Beta = 0.853; 95% CI 0.41–1.30; F = 9.02; p < 0.001) and daily levodopa equivalent dose (Beta = 0.274; 95% 
CI 0.07–0.47; F = 6.89; p < 0.01), but not with levodopa dose alone (Fig. 4b).
For the subanalysis of the group with an age at onset younger than 50 years, this group presented with a 
higher rate of ICDs (19.78%) and differences on the cultural level. Other features such as a premorbid impulsive 
personality, non-motor symptoms according to NMSS and BDI and poorer quality of life were similar to the 
Figure 2.  Mean nonmotor symptoms scale domain score in patients with Parkinson’s disease according to the 
presence of impulse control disorders. Multivariate linear regression adjusted by age, age at disease onset and 
years of disease evolution. *Statistically significant (p < 0.05). ICD impulse control disorders.
Figure 3.  39 items Parkinson’s disease Questionaire (PDQ-39) domains in Parkinson’s disease patients 
according to the presence of impulse control disorders. Score expressed by a percentage (0–100%). Multivariate 
linear regression adjusted by age, age at disease onset and years of disease evolution. *Statistically significant 
(p < 0.05). ICD impulse control disorders.
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entire sample. In the same line with the global analysis, a higher rate in the FOG scale was shown in the group 
under 50 years old (Supplementary Material, Tables 4 and 5). In the DA treatment group, the results were also 
similar except for poorer motor performance in off in patients with ICDs (22.31 ± 10.43 vs. 25.46 ± 13.16; p = 0.02) 
(Supplementary Material, Tables 2 and 3).
Discussion
The objective of the present study was to assess ICDs and CBs in patients with PD and CS, as well as the clinical 
features linked to these disorders in both groups. We found that in the patients with PD, ICDs and CBs were more 
frequent compared with the CS (ICDs 12.7% vs. 1.6%, respectively; p < 0.001; CBs 7.18% vs. 1.67%, respectively; 
p = 0.01). The proportion of ICDs found in our sample was similar to that reported in the DOMINION  study2, 
which is the largest PD prevalence study to date, in which they found ICDs in 13.2% of cases, in accordance with 
our study and with other European  works17. This result is in contrast to the high rate of ICDs found in some other 
European studies, including in the Spanish  population3,10,11. The prospective Italian study, ICARUS, had found a 
rate of ICDs at the basal evaluation of 29.3%, which was higher than in our baseline assessment in  COPPADIS3. 
These discrepancies could partially be explained by the sociocultural differences in both groups and by the dif-
fering tools used for ICDs screening. In the ICARUS study, the Minnesota Impulsive Disorders Interview (MIDI) 
and QUIP were used, whereas in COPPADIS, the QUIP-RS was applied. Following the MDS recommendations, 
QUIP-RS has more accurate clinimetric properties for application in PD, being “recommended,” whereas MIDI 
lacks some criteria validity when compared with the QUIP-RS18. In addition, ICDs screening using QUIP could 
overestimate ICDs frequency since Papay et al. found that, up to 40% of patients who scored positive for ICDs 
on the QUIP did not fulfil the diagnosis of  ICDs19. However, the QUIP-RS used in COPPADIS has stricter ICDs 
diagnostic criteria; thus, the proportion found in our study could be more accurate for the identification of ICDs.
On the other hand and in contrast to two Spanish studies, Vela et al. had found an ICDs estimation that 
reached 58.3% in their cohort of early-onset PD; and in their study of patients undergoing DA treatment, 
García-Ruiz et al. found this rate increased up to 39.1%10,11. In COPPADIS, when we analysed these two groups 
separately, the prevalence of ICDs reached 15.87% in patients with PD undergoing DA treatment and 19.78% in 
patients with an age at disease onset younger than 50 years. Again, these differences could be justified by the dif-
ferent estimation of ICDs provided by QUIP as screening tool that could overestimate the prevalence of  ICDs19.
Accounting for the features in PD and CS, we observed that a previous history of ICDs as well as premorbid 
impulsive personality were more frequent in patients with PD than in CS. A higher rate of antidepressant treat-
ment was also shown in patients with PD, which could be an intrinsic feature of PD, given a higher burden of 
nonmotor symptoms is present compared with CS, and consequently, depression is also more  frequent7,8.
In the PD group, as previous studies have reported, those who had ICDs were younger and their disease 
onset was  earlier2, 3,10,11,20. On the other hand, and in contrast to previous studies, in our cohort, ICDs were not 
related to a longer disease duration, nor a higher exposure to  DRT3,21,22. This result is interesting, given previous 
studies had hypothesised that the presence of ICDs in young patients could be explained by a dysfunction of the 
mesocorticolimbic loop due to the influence of the DRT on a relatively preserved ventral  striatum23. However, 
Table 4.  Dopaminergic replacement treatment and its relationship with impulse control disorders. Results for 
univariate tests: chi-square test, t test or Wilcoxon test. ICDs impulse control disorders, N number of subjects, 
DA dopamine agonists, SD standard deviation. *Results for multivariate analysis: multivariate linear regression 
or multivariate logistic regression adjusted by age, age at onset, years of disease progression.
ICDs negative ICDs positive P value
Dopaminergic agonists N (%) 355 (66.35%) 67 (85.9%) 0.006*
L-DOPA N (%) 381 (71.2%) 60 (76.9%) 0.59
MAO-B inhibitors N (%) 384 (71.7%) 64 (82%) 0.18
DA equivalent dose Mean ± SD 174.72 ± 164.92 237.65 ± 194.72 0.02*
LDOPA daily dose Mean ± SD 339.3 ± 307.9 388.01 ± 310.12 0.57
LDOPA equivalent daily dose Mean ± SD 539.02 ± 405.63 636.99 ± 450.35 0.25
Time on LDOPA Months (mean ± SD) 32.99 ± 44.49 39.23 ± 41.79 0.91
Time on agonists Months (mean ± SD) 33.62 ± 41.95 45.86 ± 42.34 0.14
Table 5.  Comparison among patients on different agonists with those without them and the relationship to 
impulse control disorders. Results for multivariate logistic regression adjusted by age, age onset and years of 
disease. ICDs impulse control disorders, N number of subjetcs, OR odds ratio, CI confidence interval.
N ICDs P value
Pramipexole 208 32 (15.4%) p = 0.017 (OR 2.47; CI 95% 1.2–5.42)
Ropinirole 107 18 (16.8%) p = 0.013 (OR 2.82; CI 95% 1.25–6.57)
Rotigotine 99 15 (15.5%) p = 0.03 (OR 2.45; CI 95% 1.06–5.8)
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Figure 4.  (a) Relationship between severity of impulse control disorders and type of dopamine agonist in 
patients with impulse control disorders positive (PC + ICD) and negative (PD-ICD). NS Not significant (b) 
Relationship between severity of impulse control disorders and dopaminergic treatment dose.
9
Vol.:(0123456789)
Scientific RepoRtS |        (2020) 10:16893  | https://doi.org/10.1038/s41598-020-73756-z
www.nature.com/scientificreports/
recent studies have supported the contrary version given that, reduced dopamine synthesis capacity in the nucleus 
accumbens as well as reduced functional connectivity in this area have been  shown9,24. Consequently, the higher 
rate of ICDs in young patients could not be fully explained by the neurodegenerative pattern progression. Genetic 
factors could instead be involved in the early disease onset and ICDs in these  patients5,25.
In patients with PD who have ICDs, a premorbid history of ICDs and impulsive personality were more 
frequent, according to observations in previous studies developed in European countries and  worldwide2,17,26.
Concerning motor performance, in our case and according to the vast majority of studies, the motor status 
did not differ in patients with  ICDs3,10,11. However, it is interesting to note that, although the motor performance 
according to the UPDRS III was not different according to the presence of ICDs, the scores on the FOG scale 
were higher in patients with ICDs. This observation was similar in the subgroup of early disease onset, suggesting 
a shared physiopathological background or due to the perception of the patients since a poorer status was also 
found in the motor subdomain of the PDQ-39 in patients with ICDs.
The neuropsychiatric sphere is highly impaired in patients with ICDs, as is shown in multiple  studies3,14. In 
COPPADIS, we found a high rate of depression as well as a poorer perception of mood disturbances according 
to the NMSS, PDQ-39 and NPI. The link between mood and impulsivity is not fully understood because it is 
not clear whether there is a predisposing factor or whether it is simply a consequence of the  ICDs6–8. Indeed, it 
is difficult to elucidate by the comorbidity of both disorders. However, we must take into account that there are 
genetic forms of PD with prominent nonmotor manifestations, and a common genetic background could there-
fore underlie both, mood disorders and  ICDs27–29. In COPPADIS, depression was more frequent in patients with 
PD compared with CS, which could suggest it as an intrinsic feature of PD rather than a consequence of ICDs. 
On the other hand, and also correlated with mood disorders, sleep disturbances are usually present in patients 
with  ICDs30–32. The relationship could again be bidirectional, as in depression, but it also appears that there is 
a shared neurobiological substrate, given some genetic risk factors might justify the coexistence of both ICDs 
and sleep  problems33. On the other hand, the intake of antidepressant drugs was not different between patients 
with ICDs positive or negative in the whole cohort. This observation is important since it could point out to a 
infradiagnosis of depression in patients with ICDs.
Apart from the impact of neuropsychiatric symptoms and sleep, in line with previous  studies3, other nonmo-
tor symptoms were more prominent in patients with ICDs. Urinary and cardiovascular symptoms were more 
frequent in patients with ICDs, in agreement with the Italian study ICARUS and other series. It is interesting 
to note that these patients present with a high burden of nonmotor symptoms from different spheres; thus, we 
should keep this into mind when performing an integral assessment in this particular group of individuals.
Concerning cognitive performance related to ICDs, we did not find any difference between the groups, even 
when analysing the subgroups of patients undergoing DA treatment or early-onset PD. It contrasts with the 
abnormalities noted in other studies in which executive dysfunction as well as impairment in the reward-related 
decision process and set shifting have been  noticed13,14,34. In COPPADIS, the global cognition did not differ 
between groups. Analysing the frontal-subcortical domains of PD-CRS separately, no differences were found. To 
better understand the reasons for these discrepancies, future neuroimaging studies would be useful to determine 
the functionality of this area in our cohort.
Regarding the DRT and its influence on ICDs, we found that DA use had greater impact on ICDs; it was 
dose-dependent and related to severity, which was in line with the observation noted in multiple studies across 
 populations2,10,11,35. However, the risks linked to the type of agonist can be different. We found, according to 
another Spanish study and a European multicentre study, that Rotigotine had a low risk of developing ICDs, 
and Ropirinole the  highest11,36. As Rizos et al. explained, the association between Rotigotine and ICDs is poorly 
understood, but it could be associated with its mechanism of action from continuous dopaminergic  stimulation37. 
This possibility is important, given we could consider this in patients with other risk factors for ICDs in the case 
that DA treatment is required.
On the other hand, it is interesting to highlight the fact that longer levodopa or DA exposure was not related 
to the appearance of ICDs; thus, ICDs could appear at any time in the disease course. Therefore, clinicians should 
be aware of and investigate ICDs over time.
This study has some limitations. The presented data correspond to the cross-sectional evaluation at baseline of 
COPPADIS cohort, nevertheless, the assessment of the ICDs/CBs behaviour over time would be more informa-
tive. This issue would be overcome in the future since the follow up of this cohort is on-going and we will obtain 
the longitudinal  data38. On the other hand, following the methodology of the study, the UPDRS part II evaluation 
only included motor items to assess the phenotype (tremor dominant, postural instability and gait disorders or 
undetermined). It would be more accurate to evaluate the whole UPDRS part II to establish the handicaps in 
the performance of the daily activities according this scale. To partially compensate this issue, we assessed the 
PDQ-39 that also included activities of daily living.
conclusions
ICDs and CBs are common nonmotor features in patients with PD compared with CS. Some premorbid features 
such as a previous impulsive personality act as risk factors for developing these disorders. DRT had a large impact 
on ICDs, and DAs were the drugs with the greatest effect. However, patients with ICDs had a high burden of 
nonmotor symptoms belonged to mood, cardio-vascular, sleep, urinary domains among others as well as a poor 
quality of life. Hence, apart from treatment, patients might have a genetic background that could influence the 
presence of a prominent non-motor phenotype.
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